Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026
Globe Newswire•03/11/2026•08:00 ET
0
Key Highlights
- ➤Q3 2026 financial results scheduled for November 13 before market open
- ➤Milestone (MIST) will provide a business update alongside quarterly results
- ➤CARDAMYST (etripamil) is FDA-approved for acute PSVT conversion in adults
- ➤Etripamil is in Phase 3 development for symptomatic episodic AFib attacks
MONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Milestone(®) Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report its financial results for the third quarter ended September 30, 2026, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30 am ET.
To access the live conference call, participants may register here.
Get started
Create a free account to read the full story.